SOPHiA GENETICS, a leading health tech company, announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine.
Read More »
EXELIXIS: Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
VAST THERAPEUTICS: Announces Results Showing Ability to Eradicate Anthrax
ACTINIUM PHARMACEUTICALS: Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies